SARS-CoV-2 Papain-Like Protease: Drug Design, Assay Development, and Drug Resistance.

Wang J, Li K, Tan B

DOI: 10.1021/acs.accounts.6c00361
Published: 2026 Sep 1
Container: Accounts of chemical research
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1021/acs.accounts.6c00361,
  title = {SARS-CoV-2 Papain-Like Protease: Drug Design, Assay Development, and Drug Resistance.},
  author = {Wang J and Li K and Tan B},
  year = {2026},
  journal = {Accounts of chemical research},
  doi = {10.1021/acs.accounts.6c00361},
  url = {https://doi.org/10.1021/acs.accounts.6c00361}
}

RIS

TY  - JOUR
TI  - SARS-CoV-2 Papain-Like Protease: Drug Design, Assay Development, and Drug Resistance.
AU  - Wang J
AU  - Li K
AU  - Tan B
PY  - 2026
JO  - Accounts of chemical research
DO  - 10.1021/acs.accounts.6c00361
UR  - https://doi.org/10.1021/acs.accounts.6c00361
ER  -

APA

J, W., K, L., & B, T. (2026). SARS-CoV-2 Papain-Like Protease: Drug Design, Assay Development, and Drug Resistance.. Accounts of chemical research. https://doi.org/10.1021/acs.accounts.6c00361

Source records

pubmed · retrieved 2026-09-26T20:01:07.794Z